• Home
  • Media
  • Events
  • Julphar partakes in Duphat 2014 to consolidate its role in the regional and global healthcare sector

Julphar partakes in Duphat 2014 to consolidate its role in the regional and global healthcare sector

2014-03-10

Julphar, the UAE leading pharmaceutical company in the MENA region, is a major partner in the Dubai International Pharmaceuticals and Technologies Conference and Exhibition (Duphat) 2014, kick-starting this week in Dubai, under the patronage of H.H. Sheikh Hamdan Bin Rashid Al Maktoum, Deputy Ruler of Dubai, Minister of Finance, UAE, and President of Dubai Health Authority.

Duphat 2014 provides an opportunity to update various pharma stakeholders on the new trends and latest relevant technologies that can optimise the quality of the industry practice, strategies and research. Prominent figures and experts from around the world will enrich the conference and exhibition with their experiences and achievements in the pharma field.

Over the past 3 decades, Julphar has made the transition from a local UAE company to a truly global player, distributing to areas as far as South East Asia and Latin America, and leading efforts in the region to enhance access to quality healthcare by producing safe and affordable medicines. Not only that, Julphar has also made biosimilars breakthrough by producing the raw material needed to make insulin, a first in the region.

"Duphat 2014 is happening at a moment where the issue of quality healthcare has gained stronger traction as governments are grappling with the issue of ensuring quality healthcare and controlling rising cost. Julphar works alongside the government and regulatory bodies, as we aim to reduce healthcare expenditure by producing medicines which are safe, effective and come at a lower cost." said Basel Aboujalala, Julphar 's GCC Director.

"We are keen on Duphat 2014 to engage in discussions about healthcare challenges and solutions with global and regional players from both the public and private sector, as well as identify new trends and future investment opportunities in the pharmaceutical industry" added Basel.

Julphar is the first Emirati pharmaceutical company and leads the industry in the MENA region with 3843 products andregistered sales revenue of AED 1,362.1 million in 2013. Also, Julphar has the capacity to be among theworld's top producers of insulin and is the first and only producer in the region of the raw material used in making insulin. Julphar manages a diverse portfolio of therapeutic products, covering a wide range of major pharmaceutical segments, including consumer, endocrinology, antibiotics, cardiovascular, women's health, dermatology, gastroenterology, metabolic, nephrology, wound and scar and respiratory. 

This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, refer to our Cookie Policy.